Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603520.SS Stock Summary
Top 10 Correlated ETFs
603520.SS
In the News
603520.SS Financial details
Company Rating
Buy
Market Cap
4.23B
Income
-61.76M
Revenue
2.39B
Book val./share
5.13
Cash/share
2.3
Dividend
0.2
Dividend %
1.53%
Employees
1.84K
Optionable
No
Shortable
Yes
Earnings
19 Apr 2024
P/E
-69.42
Forward P/E
8.95
PEG
5.84
P/S
1.88
P/B
2.44
P/C
5.13
P/FCF
-16.15
Quick Ratio
0.45
Current Ratio
0.82
Debt / Equity
1.83
LT Debt / Equity
0.46
-
-
EPS (TTM)
-0.18
EPS next Y
1.32
EPS next Q
-
EPS this Y
-122.34%
EPS next Y
-843.24%
EPS next 5Y
-843.24%
EPS last 5Y
NAN%
Revenue last 5Y
19.07%
Revenue Q/Q
5.61%
EPS Q/Q
-85.36%
-
-
-
-
SMA20
20%
SMA50
-14.29%
SMA100
-20%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-4%
ROC
-0.02%
Gross Margin
23%
Oper. Margin
-2%
Profit Margin
-3%
Payout
-280%
Shs Outstand
342.51M
Shs Float
202.51M
-
-
-
-
Target Price
-
52W Range
7.86-19.37
52W High
-37.84%
52W Low
+68.71%
RSI
52
Rel Volume
0.97
Avg Volume
6.76M
Volume
6.55M
Perf Week
-10.46%
Perf Month
40.6%
Perf Quarter
-
Perf Half Y
-23.21%
-
-
-
-
Beta
0.486
-
-
Volatility
0.4%, 1.2%
Prev Close
-1.01%
Price
11.81
Change
-3.04%
603520.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.72 | 3.98 | 4.09 | 5.87 | 6.23 | |
Net income per share | 0.29 | 0.52 | 0.71 | 0.95 | -0.21 | |
Operating cash flow per share | 0.59 | 0.75 | 0.52 | 1.49 | -0.23 | |
Free cash flow per share | 0.09 | 0.35 | 0.06 | 0.6 | -1.61 | |
Cash per share | 0.53 | 1.29 | 2.78 | 2.48 | 1.94 | |
Book value per share | 2.72 | 3.03 | 5.46 | 6.38 | 5.16 | |
Tangible book value per share | 0.57 | 0.94 | 3.4 | 4.25 | 3.04 | |
Share holders equity per share | 2.72 | 3.03 | 5.46 | 6.38 | 5.16 | |
Interest debt per share | 5.83 | 6.58 | 6.51 | 5.81 | 8.4 | |
Market cap | 3.05B | 7.12B | 15.71B | 15.82B | 6.7B | |
Enterprise value | 4.71B | 8.77B | 17B | 16.96B | 8.82B | |
P/E ratio | 32.59 | 41.82 | 65.83 | 48.87 | -93.12 | |
Price to sales ratio | 3.43 | 5.44 | 11.5 | 7.91 | 3.14 | |
POCF ratio | 15.91 | 28.87 | 90.07 | 31.1 | -85.46 | |
PFCF ratio | 103.71 | 62.77 | 737.34 | 77.2 | -12.17 | |
P/B Ratio | 3.43 | 7.15 | 8.62 | 7.28 | 3.79 | |
PTB ratio | 3.43 | 7.15 | 8.62 | 7.28 | 3.79 | |
EV to sales | 5.29 | 6.7 | 12.43 | 8.48 | 4.14 | |
Enterprise value over EBITDA | 17.12 | 19.93 | 32.24 | 26.49 | 28.19 | |
EV to operating cash flow | 24.57 | 35.54 | 97.42 | 33.32 | -112.52 | |
EV to free cash flow | 160.13 | 77.28 | 797.56 | 82.72 | -16.02 | |
Earnings yield | 0.03 | 0.02 | 0.02 | 0.02 | -0.01 | |
Free cash flow yield | 0.01 | 0.02 | 0 | 0.01 | -0.08 | |
Debt to equity | 2.07 | 2.09 | 1.14 | 0.88 | 1.58 | |
Debt to assets | 0.6 | 0.6 | 0.47 | 0.39 | 0.52 | |
Net debt to EBITDA | 6.03 | 3.74 | 2.43 | 1.77 | 6.78 | |
Current ratio | 0.77 | 0.77 | 1.27 | 1.09 | 0.79 | |
Interest coverage | 1.95 | 4.01 | 4.36 | 5.42 | 1.65 | |
Income quality | 2.01 | 1.35 | 0.69 | 1.54 | 1.09 | |
Dividend Yield | 0.04 | 0.02 | 0.01 | 0.01 | 0.03 | |
Payout ratio | 1.16 | 0.69 | 0.62 | 0.62 | -3.03 | |
Sales general and administrative to revenue | 0.05 | 0.04 | 0.05 | 0.03 | 0.03 | |
Research and developement to revenue | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | |
Intangibles to total assets | 0.24 | 0.21 | 0.17 | 0.16 | 0.14 | |
Capex to operating cash flow | -0.85 | -0.54 | -0.88 | -0.6 | 6.02 | |
Capex to revenue | -0.18 | -0.1 | -0.11 | -0.15 | -0.22 | |
Capex to depreciation | -1.92 | -1.22 | -1.21 | -1.96 | -2.94 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.18 | 5.95 | 9.36 | 11.68 | 4.94 | |
ROIC | 0.04 | 0.09 | 0.09 | 0.08 | 0.04 | |
Return on tangible assets | 0.04 | 0.06 | 0.06 | 0.08 | -0.02 | |
Graham Net | -4.59 | -4.73 | -3.02 | -3.1 | -5.7 | |
Working capital | -294.67M | -362.64M | 407.83M | 175.75M | -588.15M | |
Tangible asset value | 186.4M | 307.26M | 1.14B | 1.45B | 1.04B | |
Net current asset value | -1.18B | -1.23B | -608.06M | -619.03M | -1.36B | |
Invested capital | 2.07 | 2.09 | 1.14 | 0.88 | 1.58 | |
Average receivables | 295.28M | 343.91M | 398.6M | 568.11M | 711.9M | |
Average payables | 141.73M | 257.95M | 295.45M | 443.44M | 565.79M | |
Average inventory | 357.96M | 427.07M | 480.71M | 527.07M | 628.09M | |
Days sales outstanding | 137.01 | 98.6 | 118.45 | 126.4 | 125.23 | |
Days payables outstanding | 152.13 | 143.61 | 141.06 | 172.29 | 121.9 | |
Days of inventory on hand | 295.58 | 206.87 | 255.75 | 150.9 | 166.53 | |
Receivables turnover | 2.66 | 3.7 | 3.08 | 2.89 | 2.91 | |
Payables turnover | 2.4 | 2.54 | 2.59 | 2.12 | 2.99 | |
Inventory turnover | 1.23 | 1.76 | 1.43 | 2.42 | 2.19 | |
ROE | 0.11 | 0.17 | 0.13 | 0.15 | -0.04 | |
Capex per share | -0.5 | -0.41 | -0.46 | -0.89 | -1.38 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.79 | 2.2 | 1.77 | 1.62 | 1.6 | |
Net income per share | -0.17 | -0.3 | 0.03 | 0.08 | 0.01 | |
Operating cash flow per share | -0.17 | -0.3 | 0.03 | -0.01 | 0.28 | |
Free cash flow per share | -0.66 | -0.49 | -0.22 | -0.27 | 0.14 | |
Cash per share | 2.96 | 1.94 | 2.44 | 1.68 | 2.3 | |
Book value per share | 7.62 | 5.16 | 5.57 | 5.47 | 5.13 | |
Tangible book value per share | 4.29 | 3.04 | 3.3 | 3.21 | 3.04 | |
Share holders equity per share | 7.62 | 5.16 | 5.57 | 5.47 | 5.13 | |
Interest debt per share | 11.35 | 8.21 | 9.54 | 9.31 | 9.47 | |
Market cap | 4.18B | 6.7B | 6.06B | 5.32B | 5.3B | |
Enterprise value | 6.2B | 8.82B | 8.29B | 7.71B | 7.71B | |
P/E ratio | -26.04 | -16.57 | 158.25 | 51.73 | 327.55 | |
Price to sales ratio | 9.62 | 8.88 | 10.7 | 10.27 | 9.68 | |
POCF ratio | -104.14 | -66.26 | 633 | -2.94K | 55.5 | |
PFCF ratio | -26.19 | -40.25 | -86.17 | -60.96 | 114.16 | |
P/B Ratio | 2.26 | 3.79 | 3.41 | 3.05 | 3.01 | |
PTB ratio | 2.26 | 3.79 | 3.41 | 3.05 | 3.01 | |
EV to sales | 14.26 | 11.69 | 14.65 | 14.88 | 14.09 | |
Enterprise value over EBITDA | -217.55 | 152.2 | 213.29 | 174.44 | 192.84 | |
EV to operating cash flow | -154.42 | -87.24 | 866.76 | -4.26K | 80.76 | |
EV to free cash flow | -38.84 | -52.99 | -118 | -88.34 | 166.12 | |
Earnings yield | -0.01 | -0.02 | 0 | 0 | 0 | |
Free cash flow yield | -0.04 | -0.02 | -0.01 | -0.02 | 0.01 | |
Debt to equity | 1.48 | 1.58 | 1.7 | 1.69 | 1.83 | |
Debt to assets | 0.52 | 0.52 | 0.55 | 0.54 | 0.56 | |
Net debt to EBITDA | -70.83 | 36.6 | 57.52 | 54.06 | 60.32 | |
Current ratio | 0.85 | 0.79 | 0.82 | 0.73 | 0.82 | |
Interest coverage | -0.39 | -3.46 | 0.38 | 1.04 | 0.29 | |
Income quality | 1 | 1 | 1 | -0.07 | 23.61 | |
Dividend Yield | 0.01 | 0 | 0 | 0.02 | 0 | |
Payout ratio | -0.71 | -0.25 | 3.08 | 3.71 | 5.62 | |
Sales general and administrative to revenue | 0.17 | -0.05 | 0.05 | 0 | 0.12 | |
Research and developement to revenue | 0.08 | 0.05 | 0.06 | 0.06 | 0.07 | |
Intangibles to total assets | 0.15 | 0.14 | 0.13 | 0.13 | 0.13 | |
Capex to operating cash flow | 2.98 | 0.65 | -8.35 | 47.24 | -0.51 | |
Capex to revenue | -0.27 | -0.09 | -0.14 | -0.16 | -0.09 | |
Capex to depreciation | -2.69 | -1.47 | -1.8 | -1.93 | 0 | |
Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0 | |
Graham number | 5.32 | 5.85 | 1.94 | 3.15 | 1.17 | |
ROIC | 0 | -0.02 | 0 | 0.01 | 0 | |
Return on tangible assets | -0.01 | -0.02 | 0 | 0.01 | 0 | |
Graham Net | -7.51 | -5.7 | -6.3 | -6.93 | -6.4 | |
Working capital | -403.16M | -588.15M | -517.73M | -820.26M | -544.24M | |
Tangible asset value | 1.04B | 1.04B | 1.05B | 1.02B | 1.04B | |
Net current asset value | -1.24B | -1.36B | -1.39B | -1.47B | -1.45B | |
Invested capital | 1.48 | 1.58 | 1.7 | 1.69 | 1.83 | |
Average receivables | 730.32M | 715.47M | 740.08M | 676.68M | 584.77M | |
Average payables | 526.31M | 524.48M | 530M | 533.49M | 535.6M | |
Average inventory | 705.86M | 750.91M | 762.47M | 897.98M | 1.04B | |
Days sales outstanding | 144.9 | 87.26 | 119.11 | 105.02 | 92.98 | |
Days payables outstanding | 129.36 | 81.29 | 103.92 | 130.14 | 116.12 | |
Days of inventory on hand | 194.23 | 111.06 | 157.34 | 239.95 | 237.29 | |
Receivables turnover | 0.62 | 1.03 | 0.76 | 0.86 | 0.97 | |
Payables turnover | 0.7 | 1.11 | 0.87 | 0.69 | 0.78 | |
Inventory turnover | 0.46 | 0.81 | 0.57 | 0.38 | 0.38 | |
ROE | -0.02 | -0.06 | 0.01 | 0.01 | 0 | |
Capex per share | -0.49 | -0.19 | -0.25 | -0.27 | -0.14 |
603520.SS Frequently Asked Questions
What is Zhejiang Starry Pharmaceutical Co.,Ltd. stock symbol ?
Zhejiang Starry Pharmaceutical Co.,Ltd. is a CN stock and trading under the symbol 603520.SS
What is Zhejiang Starry Pharmaceutical Co.,Ltd. stock quote today ?
Zhejiang Starry Pharmaceutical Co.,Ltd. stock price is $11.81 today.
Is Zhejiang Starry Pharmaceutical Co.,Ltd. stock public?
Yes, Zhejiang Starry Pharmaceutical Co.,Ltd. is a publicly traded company.